Waldenstrom Macroglobulinemia Fund

Waldenstrom’s macroglobulinemia (WM) is a rare blood cancer affecting approximately 3 in every million people annually in the United States. Predominantly diagnosed in older adults, most patients are around the age of 70 when diagnosed, with men being twice as likely to develop WM as women. The condition is also more common among White individuals compared to other racial groups. WM leads to the overproduction of abnormal white blood cells, resulting in symptoms such as extreme fatigue, swollen lymph nodes, unexplained weight loss, night sweats, and occasional nose or mouth bleeding.

Although WM is generally incurable, it can often be managed as a chronic condition. Diagnosis involves detecting specific proteins in the blood and analyzing bone marrow samples. Treatment options have advanced over time and may include targeted therapies, antibody treatments, chemotherapy, and other medications to control the disease. Ongoing research aims to develop new treatments for patients who do not respond well to existing therapies. Despite improved survival rates with newer treatments, challenges remain, such as addressing disparities in disease impact across different racial groups and managing treatment side effects.